nach oben

Erschienen in:

14.02.2024 | Research

The role of spine stereotactic radiosurgery for patients with breast cancer metastases

verfasst von: Suchet Taori, Samuel Adida, Anthony Tang, Akshath Rajan, Roberta K. Sefcik, Steven A. Burton, John C. Flickinger, Pascal O. Zinn, Peter C. Gerszten

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Breast cancer that metastasizes to the spine is associated with low quality of life and poor survival. Radiosurgery has an increasing role in this patient population. This single-institution (2003–2023) study analyzes clinical outcomes and prognostic factors for patients who underwent spinal stereotactic radiosurgery (SSRS) for metastatic breast cancer.

Methods

Ninety patients (155 unique breast cancer spinal metastases) were treated with SSRS. The median age was 57 years (range: 35–88), and the median KPS was 80 (range: 40–100). Forty-two (27%) lesions were managed surgically prior to radiosurgery. At SSRS, 75 (48%) lesions impinged or compressed the spinal cord per the epidural spinal cord scale (ESCC). Seventy-nine (51%) lesions were categorized as potentially unstable or unstable by the Spinal Instability Neoplastic Score (SINS).

Results

The median follow-up was 15 months (range: 1–183). The median single-session tumor volume was 25.4 cc (range: 2–197), and the median single-fraction prescription dose was 17 Gy (range: 12–25). Seven (5%) lesions locally progressed. The 1-, 2-, and 5-year local control rates were 98%, 97%, and 92%, respectively. The median overall survival (OS) for the cohort was 32 months (range: 2–183). The 1-, 2-, and 5-year OS rates were 72%, 53%, and 30%, respectively. On univariate analysis, KPS ≥ 80 (p = 0.009, HR: 0.51, 95% CI: 0.31–0.84) was associated with improved OS. Patient-reported pain improved (68%), remained stable (29%), or worsened (3%) following radiosurgery. Fifteen (10%) radiation-induced toxicities were reported.

Conclusions

Spinal radiosurgery is a safe and highly effective long-term treatment modality for metastases to the spine that originate from breast cancer.

Seferis C, Torrens M, Paraskevopoulou C, Psichidis G (2014) Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J Neurosurg 121(Suppl):160–166. https://doi.org/10.3171/2014.7.GKS141311CrossRefPubMed

Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J (2015) Breast cancer: epidemiology and etiology. Cell Biochem Biophys 72:333–338. https://doi.org/10.1007/s12013-014-0459-6CrossRefPubMed

Orranti a-Borunda E, Anchondo-Nunez P, Acuna-Aguilar LE, Gomez-Valles FO, Ramirez-Valdespino CA (2022) Subtypes of breastcancer. In: Mayrovitz HN (ed) Breast cancer. Exon Publications, Brisbane (AU). https://doi.org/10.36255/exon-publications-breast-cancer-subtypesCrossRef

Ju DG, Yurter A, Gokaslan ZL, Sciubba DM (2014) Diagnosis and surgical management of breast cancer metastatic to the spine. World J Clin Oncol 5:263–271. https://doi.org/10.5306/wjco.v5.i3.263CrossRefPubMedPubMedCentral

Shehadi JA, Sciubba DM, Suk I, Suki D, Maldaun MV, McCutcheon IE, Nader R, Theriault R, Rhines LD, Gokaslan ZL (2007) Surgical treatment strategies and outcome in patients with breast cancer metastatic to the spine: a review of 87 patients. Eur Spine J 16:1179–1192. https://doi.org/10.1007/s00586-007-0357-3CrossRefPubMedPubMedCentral

Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A (2016) Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. Cancer Metastasis Rev 35:427–437. https://doi.org/10.1007/s10555-016-9631-3CrossRefPubMed

Guo Y, Arciero CA, Jiang R, Behera M, Peng L, Li X (2020) Different breast cancer subtypes show different metastatic patterns: a study from a large public database. Asian Pac J Cancer Prev 21:3587–3593. https://doi.org/10.31557/APJCP.2020.21.12.3587CrossRefPubMedPubMedCentral

Tahara RK, Brewer TM, Theriault RL, Ueno NT (2019) Bone metastasis of breast cancer. Adv Exp Med Biol 1152:105–129. https://doi.org/10.1007/978-3-030-20301-6_7CrossRefPubMed

Abrahm JL, Banffy MB, Harris MB (2008) Spinal cord compression in patients with advanced metastatic cancer: “all I care about is walking and living my life.” JAMA 299:937–946. https://doi.org/10.1001/jama.299.8.937CrossRefPubMed

10.

Sciubba DM, Petteys RJ, Dekutoski MB, Fisher CG, Fehlings MG, Ondra SL, Rhines LD, Gokaslan ZL (2010) Diagnosis and management of metastatic spine disease. A review. J Neurosurg Spine 13:94–108. https://doi.org/10.3171/2010.3.SPINE09202CrossRefPubMed

11.

Tancioni F, Navarria P, Mancosu P, Pedrazzoli P, Morenghi E, Santoro A, Baena RR, Scorsetti M (2011) Surgery followed by radiotherapy for the treatment of metastatic epidural spinal cord compression from breast cancer. Spine (Phila Pa 1976) 36:E1352-1359. https://doi.org/10.1097/BRS.0b013e318207a222CrossRefPubMed

12.

Zadnik PL, Hwang L, Ju DG, Groves ML, Sui J, Yurter A, Witham TF, Bydon A, Wolinsky JP, Gokaslan ZL, Sciubba DM (2014) Prolonged survival following aggressive treatment for metastatic breast cancer in the spine. Clin Exp Metastasis 31:47–55. https://doi.org/10.1007/s10585-013-9608-3CrossRefPubMed

13.

Tan KA, Tan JH, Zaw AS, Tan JYH, Hey HWD, Kumar N (2018) Evaluation of prognostic factors and proposed changes to the modified tokuhashi score in patients with spinal metastases from breast cancer. Spine (Phila Pa 1976) 43:512–519. https://doi.org/10.1097/BRS.0000000000002350CrossRefPubMed

14.

Bollen L, Wibmer C, Wang M, van der Linden YM, Leithner A, Bunger CE, Jensen AB, Fiocco M, Bratschitsch G, Pondaag W, Bovee JV, Dijkstra PD (2015) Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases. Clin Exp Metastasis 32:1–5. https://doi.org/10.1007/s10585-014-9685-yCrossRefPubMed

15.

Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61. https://doi.org/10.1186/s13058-020-01296-5CrossRefPubMedPubMedCentral

16.

Chen WZ, Shen JF, Zhou Y, Chen XY, Liu JM, Liu ZL (2017) Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. Sci Rep 7:11325. https://doi.org/10.1038/s41598-017-11700-4CrossRefPubMedPubMedCentral

17.

Bilsky MH, Angelov L, Rock J, Weaver J, Sheehan J, Rhines L, Azeem S, Gerszten P (2011) Spinal radiosurgery: a neurosurgical perspective. J Radiosurg SBRT 1:47–54PubMedPubMedCentral

18.

Abugharib A, Zeng KL, Tseng CL, Soliman H, Myrehaug S, Husain Z, Maralani PJ, Larouche J, Cheung P, Emmenegger U, Atenafu EG, Sahgal A, Detsky JS (2022) Spine stereotactic body radiotherapy for prostate cancer metastases and the impact of hormone sensitivity status on local control. Neurosurgery 90:743–749. https://doi.org/10.1227/neu.0000000000001909CrossRefPubMed

19.

Thibault I, Al-Omair A, Masucci GL, Masson-Cote L, Lochray F, Korol R, Cheng L, Xu W, Yee A, Fehlings MG, Bjarnason GA, Sahgal A (2014) Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. J Neurosurg Spine 21:711–718. https://doi.org/10.3171/2014.7.SPINE13895CrossRefPubMed

20.

Gerszten PC, Burton SA, Ozhasoglu C, Welch WC (2007) Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 32:193–199. https://doi.org/10.1097/01.brs.0000251863.76595.a2CrossRefPubMed

21.

Gerszten PC, Burton SA, Welch WC, Brufsky AM, Lembersky BC, Ozhasoglu C, Vogel WJ (2005) Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer 104:2244–2254. https://doi.org/10.1002/cncr.21467CrossRefPubMed

22.

Gagnon GJ, Henderson FC, Gehan EA, Sanford D, Collins BT, Moulds JC, Dritschilo A (2007) Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis. Cancer 110:1796–1802. https://doi.org/10.1002/cncr.22977CrossRefPubMed

23.

Lemoine P, Bruand M, Kammerer E, Bogart E, Comte P, Royer P, Thariat J, Pasquier D (2021) Stereotactic body radiation therapy for oligometastatic breast cancer: a retrospective multicenter study. Front Oncol 11:736690. https://doi.org/10.3389/fonc.2021.736690CrossRefPubMedPubMedCentral

24.

Bilsky MH, Laufer I, Fourney DR, Groff M, Schmidt MH, Varga PP, Vrionis FD, Yamada Y, Gerszten PC, Kuklo TR (2010) Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine 13:324–328. https://doi.org/10.3171/2010.3.SPINE09459CrossRefPubMed

25.

Fourney DR, Frangou EM, Ryken TC, Dipaola CP, Shaffrey CI, Berven SH, Bilsky MH, Harrop JS, Fehlings MG, Boriani S, Chou D, Schmidt MH, Polly DW, Biagini R, Burch S, Dekutoski MB, Ganju A, Gerszten PC, Gokaslan ZL, Groff MW, Liebsch NJ, Mendel E, Okuno SH, Patel S, Rhines LD, Rose PS, Sciubba DM, Sundaresan N, Tomita K, Varga PP, Vialle LR, Vrionis FD, Yamada Y, Fisher CG (2011) Spinal instability neoplastic score: an analysis of reliability and validity from the spine oncology study group. J Clin Oncol 29:3072–3077. https://doi.org/10.1200/JCO.2010.34.3897CrossRefPubMed

26.

Gerszten PC, Burton SA, Ozhasoglu C (2007) CyberKnife radiosurgery for spinal neoplasms. Prog Neurol Surg 20:340–358. https://doi.org/10.1159/000100177CrossRefPubMed

27.

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90–92. https://doi.org/10.1016/j.ad.2019.05.009CrossRefPubMed

28.

Peart O (2017) Metastatic breast cancer. Radiol Technol 88:519M-539MPubMed

29.

Jin X, Mu P (2015) Targeting breast cancer metastasis. Breast Cancer (Auckl) 9:23–34. https://doi.org/10.4137/BCBCR.S25460CrossRefPubMed

30.

Chan-Seng E, Charissoux M, Larbi A, Tetreau R, Gerber YN, De Verbizier-Lonjon D, Segnarbieux F, Lonjon N (2014) Spinal metastases in breast cancer: single center experience. World Neurosurg 82:1344–1350. https://doi.org/10.1016/j.wneu.2014.08.010CrossRefPubMed

31.

Maccauro G, Spinelli MS, Mauro S, Perisano C, Graci C, Rosa MA (2011) Physiopathology of spine metastasis. Int J Surg Oncol 2011:107969. https://doi.org/10.1155/2011/107969CrossRefPubMedPubMedCentral

32.

Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2008) Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 26:4289–4295. https://doi.org/10.1200/JCO.2007.15.4997CrossRefPubMed

33.

Zhao C, Zhang Z, Zhong N, Fan T, Gao X, Wu Z, Li Z, Liu T, Xiao J (2018) Outcomes and prognostic factors for surgically treated patients with breast cancer spine metastases. J Bone Oncol 12:38–43. https://doi.org/10.1016/j.jbo.2018.03.003CrossRefPubMedPubMedCentral

34.

Weigel B, Maghsudi M, Neumann C, Kretschmer R, Muller FJ, Nerlich M (1999) Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life. Spine (Phila Pa 1976) 24:2240–2246. https://doi.org/10.1097/00007632-199911010-00012CrossRefPubMed

35.

Weitao Y, Zhihuang L, Liangyu G, Limin N, Min Y, Xiaohui N (2022) Surgical efficacy and prognosis of 54 cases of spinal metastases from breast cancer. World Neurosurg 165:e373–e379. https://doi.org/10.1016/j.wneu.2022.06.060CrossRefPubMed

36.

Switlyk MD, Bruland OS, Skjeldal S, Hald JK, Seierstad T, Zaikova O (2014) Radiotherapy for spinal metastases from breast cancer with emphasis on local disease control and pain response using repeated MRI. J Bone Oncol 3:5–9. https://doi.org/10.1016/j.jbo.2014.02.003CrossRefPubMedPubMedCentral

37.

Makita K, Hamamoto Y, Kanzaki H, Kataoka M, Yamamoto S, Nagasaki K, Ishikawa H, Takata N, Tsuruoka S, Uwatsu K, Kido T (2021) Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study. Radiat Oncol 16:225. https://doi.org/10.1186/s13014-021-01940-0CrossRefPubMedPubMedCentral

38.

Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, Butler J, Chow E, Fehlings MG, Foote M, Gabos Z, Greenspoon J, Kerba M, Lee Y, Liu M, Liu SK, Thibault I, Wong RK, Hum M, Ding K, Parulekar WR, trial i (2021) Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol 22:1023–1033. https://doi.org/10.1016/S1470-2045(21)00196-0CrossRefPubMed

39.

Ryu S, Deshmukh S, Timmerman RD, Movsas B, Gerszten P, Yin FF, Dicker A, Abraham CD, Zhong J, Shiao SL, Tuli R, Desai A, Mell LK, Iyengar P, Hitchcock YJ, Allen AM, Burton S, Brown D, Sharp HJ, Dunlap NE, Siddiqui MS, Chen TH, Pugh SL, Kachnic LA (2023) Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: phase 3 results of NRG ONCOLOGY/RTOG 0631 randomized clinical trial. JAMA Oncol 9:800–807. https://doi.org/10.1001/jamaoncol.2023.0356CrossRefPubMed

40.

Zeng KL, Myrehaug S, Soliman H, Husain ZA, Tseng CL, Detsky J, Ruschin M, Atenafu EG, Witiw CD, Larouche J, da Costa L, Maralani PJ, Parulekar WR, Sahgal A (2022) Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy. Int J Radiat Oncol Biol Phys 114:293–300. https://doi.org/10.1016/j.ijrobp.2022.05.043CrossRefPubMed

41.

Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O’Shaughnessy J, Investigators K (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810–821. https://doi.org/10.1056/NEJMoa1910549CrossRefPubMed

42.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J, Committee AS, Investigators (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131. https://doi.org/10.1056/NEJMoa1703643CrossRef

43.

Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395:817–827. https://doi.org/10.1016/S0140-6736(20)30165-3CrossRefPubMed

44.

Cortesi L, Rugo HS, Jackisch C (2021) An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 16:255–282. https://doi.org/10.1007/s11523-021-00796-4CrossRefPubMedPubMedCentral

45.

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst 90:1371–1388. https://doi.org/10.1093/jnci/90.18.1371CrossRefPubMed

46.

Freedman GM, Jones JA, Taunk NK (2023) Stereotactic radiation for oligometastatic and oligoprogressive stage IV breast cancer: a case-based review. Curr Oncol 30:2510–2523. https://doi.org/10.3390/curroncol30020192CrossRefPubMedPubMedCentral

47.

Ling DC, Flickinger JC, Burton SA, Heron DE, Quinn AE, Bejjani GK, Engh JA, Gerszten PC, Amankulor NM, Vargo JA (2018) Long-term outcomes after stereotactic radiosurgery for spine metastases: radiation dose-response for late toxicity. Int J Radiat Oncol Biol Phys 101:602–609. https://doi.org/10.1016/j.ijrobp.2018.02.035CrossRefPubMedPubMedCentral

48.

Guckenberger M, Mantel F, Gerszten PC, Flickinger JC, Sahgal A, Letourneau D, Grills IS, Jawad M, Fahim DK, Shin JH, Winey B, Sheehan J, Kersh R (2014) Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol 9:226. https://doi.org/10.1186/s13014-014-0226-2CrossRefPubMedPubMedCentral

49.

Ning MS, Deegan BJ, Ho JC, Chapman BV, Bishop AJ, Allen PK, Tannir NM, Amini B, Briere TM, Wang XA, Tatsui CE, Rhines LD, Brown PD, Li J, Ghia AJ (2019) Low incidence of late failure and toxicity after spine stereotactic radiosurgery: secondary analysis of phase I/II trials with long-term follow-up. Radiother Oncol 138:80–85. https://doi.org/10.1016/j.radonc.2019.06.003CrossRefPubMed

50.

Bishop AJ, Tao R, Guadagnolo BA, Allen PK, Rebueno NC, Wang XA, Amini B, Tatsui CE, Rhines LD, Li J, Chang EL, Brown PD, Ghia AJ (2017) Spine stereotactic radiosurgery for metastatic sarcoma: patterns of failure and radiation treatment volume considerations. J Neurosurg Spine 27:303–311. https://doi.org/10.3171/2017.1.SPINE161045CrossRefPubMed

Titel: The role of spine stereotactic radiosurgery for patients with breast cancer metastases
verfasst von: Suchet Taori
Samuel Adida
Anthony Tang
Akshath Rajan
Roberta K. Sefcik
Steven A. Burton
John C. Flickinger
Pascal O. Zinn
Peter C. Gerszten
Publikationsdatum: 14.02.2024
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2024
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-024-04599-1

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Utility of molecular markers in predicting local control specific to lung cancer spine metastases treated with stereotactic body radiotherapy

Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk–benefit analysis

Hypofractionated stereotactic re-irradiation for progressive glioblastoma: twelve years’ experience of a single center

Diverse learners: learning disabilities and quality of life following mind–body and health education interventions for adults with neurofibromatosis

Repeated surgical resections for management of high-grade glioma and its impact on quality of life